PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Ran, Zhi Hua; Liu, Fang; Chen, Fang; Yang, Jing; Luo, Lifeng; Yue, Ping; Gao, Beili; Dong, Yuchao; Xiang, Yi

doi:10.3389/fimmu.2021.724443

Cited by 43 publications

(51 citation statements)

References 31 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifteen studies encompassing 4942 patients were included in the meta-analyses [ 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ]. The available studies were conducted on several tumors, including CRC, melanoma, breast cancer, and non-small cell lung cancer ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…One study evaluated both patients treated with immunotherapy (nivolumab and pembrolizumab alone) and targeted therapy with BRAF inhibitors/MEK inhibitors, and separate data for these treatment types were included in the subgroup analyses [ 32 ]. Ten studies included Caucasian patients [ 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 48 ], while five studies were conducted in the Far East [ 44 , 45 , 46 , 47 , 49 ]. Most studies had a low risk of bias according to the NOS ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

“…Fourteen studies with available DFS/PFS data were included in the analyses [ 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 48 , 49 ]. All but two studies reported significantly lower DFS/PFS with higher PIV levels, while the DFS/PFS difference did not reach statistical significance in the studies by Guven et al and Susok et al [ 39 , 42 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

Güven

Şahin

Erul

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an equation including the neutrophil, platelet, monocyte, and lymphocyte levels, has been evaluated in several cohorts, although with variations in the tumor types, disease stages, cut-offs, and treatments. Therefore, we evaluated the association between survival and PIV in cancer, performing a systematic review and meta-analysis. Methods: We conducted a systematic review from the Pubmed, Medline, and Embase databases to filter the published studies until 17 May 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model. Results: Fifteen studies encompassing 4942 patients were included. In the pooled analysis of fifteen studies, the patients with higher PIV levels had significantly increased risk of death than those with lower PIV levels (HR: 2.00, 95% CI: 1.51–2.64, p < 0.001) and increased risk of progression or death (HR: 1.80, 95% CI: 1.39–2.32, p < 0.001). Analyses were consistent across several clinical scenarios, including non-metastatic or metastatic disease, different cut-offs (500, 400, and 300), and treatment with targeted therapy or immunotherapy (p < 0.001 for each). Conclusion: The available evidence demonstrates that PIV could be a prognostic biomarker in cancer. However, further research is needed to explore the promise of PIV as a prognostic biomarker in patients with non-metastatic disease or patients treated without immunotherapy or targeted therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

Güven

Şahin

Erul

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The PIV includes four CBC-based parameters: neutrophil, platelet, monocyte, and lymphocyte counts. In several studies including malignancies, such as metastatic CM, colorectal carcinoma and non-small cell lung carcinoma, PIV was independently associated with overall survival and progression-free survival (Fucà et al 2020 ; Corti et al 2021 ; Fuca et al 2021 ; Zeng et al 2021 ). Although biomarkers of systemic inflammation including NLR and PLR, have been investigated in patients with MCC, PIV has not yet been studied in this rare malignancy (Zaragoza et al 2016b ; Garnier et al 2018 ; Naseri et al 2020 ; Nghiem et al 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma

Gambichler

Saïd

Rached

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose We aimed to determine whether the pan-immune-inflammation value (PIV) of patients with Merkel cell carcinoma (MCC) at primary diagnosis differs from controls and whether it is associated with disease stage and outcome. Methods In this retrospective study, we recruited MCC patients with stage I–III. PIV was calculated from absolute complete blood cell counts obtained within one week at MCC diagnosis as follows: [neutrophils (103/mm3) × platelets (103/mm3) × monocytes (103/mm3)]/lymphocytes (103/mm3). As controls, we studied age–gender-matched cutaneous melanoma (CM, stage I–III) patients and healthy controls (HC). Univariate and multivariate statistics were used. Results The median PIV in MCC patients was significantly increased compared to both CM patients as well as healthy controls. PIV of MCC patients in stage II and III was significantly higher compared to stage I patients. ROC analysis revealed that MCC recurrence was significantly associated with a PIV greater than 372 [p < 0.0001, Youden index 0.58; hazard ratio: 4 (95% confidence interval: 1.7 to 9.2)]. In multivariate analysis, only a PIV greater than 372 and higher MCC stage were determined as independent predictors for disease recurrence. Conclusion We determined, for the first time, the prognostic ability of the promising blood-based biomarker PIV in MCC patients and observed that PIV is increased in MCC patients in dependence on disease stage and independently predicts MCC recurrence.

show abstract

“…PIV has been shown as a prognostic marker in HER-2 (+) breast cancer (14). High PIV (> median) was reported to be correlated with poor clinical outcomes in patients with small cell lung cancer (15). Fucà et al reported that, compared with SII, PIV was superior in evaluating progression-free survival and overall survival in patients with metastatic CRC (16).…”

Section: Introductionmentioning

confidence: 99%

Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer

et al. 2022

View full text Add to dashboard Cite

ObjectiveWe investigated the clinical significance of preoperative pan-immune-inflammation value (PIV) in patients with colorectal cancer (CRC).MethodsIn this retrospective study, 366 cases who underwent surgery for CRC were enrolled. Their clinical data were collected. PIV was calculated with the formula PIV = [neutrophil count (109/L)× platelet count (109/L) × monocyte count (109/L) /lymphocyte count (109/L). Patients were divided into high PIV (> median PIV) and low PIV (< median PIV) groups. The relationship between PIV and clinicopathological features of CRC was investigated. Receiver operating characteristic (ROC) curve was plotted to indicate the value of immune-inflammatory biomarkers (IIBs) in predicting the TNM stage of CRC, and the area under the curve (AUC) was calculated to evaluate the actual clinical value of IIBs. AUC > 0.5 and closer to 1 indicated the better predictive efficacy. The influencing factors of PIV in CRC were analyzed.ResultsWe found that PIV was positively correlated with tumor size (r = 0.300, p < 0.05), carcinoembryonic antigen (CEA) (r = 0.214, p < 0.05) and carbohydrate antigen 125 (CA-125) (r = 0.249, p < 0.05), but negatively correlated with albumin (Alb) (r = −0.242, p < 0.05). PIV was significantly different in patients with different tumor locations (left or right), surgical methods (laparotomy versus laparoscopic surgery) (p < 0.05), and patients with different pathological T stages, N-stage and TNM stages (p < 0.05). ROC curve analysis of IIBs showed the AUC of PIV was greater than other markers when combined with CEA or carbohydrate antigen 19–9 (CA19–9). Multivariate regression analysis identified T stage, CEA, Alb, and tumor size as the independent influential factors of PIV in CRC.ConclusionPIV is associated with the tumor stage in patients with CRC, which may be useful in preoperative assessment of CRC.

show abstract

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Cited by 43 publications

References 31 publications

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma

Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer

Contact Info

Product

Resources

About